Genmab AS vs China Resources Double-Crane Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Genmab AS (GMAB)

Q3 202629 Jun – 13 Aug 2026

▲3▼1

Genmab's pipeline wins and raised guidance offset a key trial miss

Epcoritamab combo succeeds in DLBCL Genmab's Phase 3 trial of epcoritamab plus lenalidomide met its main goal, cutting the risk of disease progression or death by about 60% in relapsed/refractory DLBCL. This supports a future label expansion and boosts confidence in the drug's commercial potential.
A positive late-stage readout directly raises the odds of future sales growth, a core driver of GMAB's value.
EU approves TEPKINLY for follicular lymphoma European regulators cleared TEPKINLY combined with lenalidomide and rituximab for relapsed/refractory follicular lymphoma, the first bispecific-based regimen approved in Europe for this setting. This opens a new, chemotherapy-free revenue stream for Genmab and AbbVie.
A new regulatory approval expands the addressable market and adds a near-term sales catalyst.
DARZALEX royalties and raised guidance J&J's DARZALEX sales hit $4.2 billion in Q2, lifting Genmab's royalty income. First-half revenue rose 25% to $2.05 billion, prompting management to raise full-year revenue and profit guidance. This steady royalty stream underpins cash flow and reduces reliance on pipeline bets.
Royalty growth and a guidance raise are direct, near-term drivers of earnings and investor confidence.
Epcoritamab monotherapy misses survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab alone did not meet its U.S. primary goal of overall survival. The drug keeps its accelerated approval, but the miss clouds the path to full approval in that setting and may delay broader use.
A failed primary endpoint for a key drug is a material setback that can weigh on the stock despite other positive news.

July 202629 Jun – 13 Aug 2026

▲3▼1

Genmab's pipeline wins and raised guidance offset a key trial miss

Epcoritamab combo succeeds in DLBCL Genmab's Phase 3 trial of epcoritamab plus lenalidomide met its main goal, cutting the risk of disease progression or death by about 60% in relapsed/refractory DLBCL. This supports a future label expansion and boosts confidence in the drug's commercial potential.
A positive late-stage readout directly raises the odds of future sales growth, a core driver of GMAB's value.
EU approves TEPKINLY for follicular lymphoma European regulators cleared TEPKINLY combined with lenalidomide and rituximab for relapsed/refractory follicular lymphoma, the first bispecific-based regimen approved in Europe for this setting. This opens a new, chemotherapy-free revenue stream for Genmab and AbbVie.
A new regulatory approval expands the addressable market and adds a near-term sales catalyst.
DARZALEX royalties and raised guidance J&J's DARZALEX sales hit $4.2 billion in Q2, lifting Genmab's royalty income. First-half revenue rose 25% to $2.05 billion, prompting management to raise full-year revenue and profit guidance. This steady royalty stream underpins cash flow and reduces reliance on pipeline bets.
Royalty growth and a guidance raise are direct, near-term drivers of earnings and investor confidence.
Epcoritamab monotherapy misses survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab alone did not meet its U.S. primary goal of overall survival. The drug keeps its accelerated approval, but the miss clouds the path to full approval in that setting and may delay broader use.
A failed primary endpoint for a key drug is a material setback that can weigh on the stock despite other positive news.

Latest29 Jun – 13 Aug 2026

▲3▼1

Genmab's pipeline wins and raised guidance offset a key trial miss

Epcoritamab combo succeeds in DLBCL Genmab's Phase 3 trial of epcoritamab plus lenalidomide met its main goal, cutting the risk of disease progression or death by about 60% in relapsed/refractory DLBCL. This supports a future label expansion and boosts confidence in the drug's commercial potential.
A positive late-stage readout directly raises the odds of future sales growth, a core driver of GMAB's value.
EU approves TEPKINLY for follicular lymphoma European regulators cleared TEPKINLY combined with lenalidomide and rituximab for relapsed/refractory follicular lymphoma, the first bispecific-based regimen approved in Europe for this setting. This opens a new, chemotherapy-free revenue stream for Genmab and AbbVie.
A new regulatory approval expands the addressable market and adds a near-term sales catalyst.
DARZALEX royalties and raised guidance J&J's DARZALEX sales hit $4.2 billion in Q2, lifting Genmab's royalty income. First-half revenue rose 25% to $2.05 billion, prompting management to raise full-year revenue and profit guidance. This steady royalty stream underpins cash flow and reduces reliance on pipeline bets.
Royalty growth and a guidance raise are direct, near-term drivers of earnings and investor confidence.
Epcoritamab monotherapy misses survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab alone did not meet its U.S. primary goal of overall survival. The drug keeps its accelerated approval, but the miss clouds the path to full approval in that setting and may delay broader use.
A failed primary endpoint for a key drug is a material setback that can weigh on the stock despite other positive news.

China Resources Double-Crane Pharmaceutical Co Ltd (600062.CG)

Q3 202615 Jul – 14 Sep 2026

▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.
This is the biggest new event of the period and the main force behind the stock's story.
Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.
It is the key financial result of the period and the main negative force on the stock.
New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.
A steady stream of pipeline wins supports long-term growth even as current earnings dip.
Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.
These are new capital-return and demand-side events that affect investor income and product demand.

August 202615 Jul – 14 Sep 2026

▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.
This is the biggest new event of the period and the main force behind the stock's story.
Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.
It is the key financial result of the period and the main negative force on the stock.
New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.
A steady stream of pipeline wins supports long-term growth even as current earnings dip.
Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.
These are new capital-return and demand-side events that affect investor income and product demand.

Latest15 Jul – 14 Sep 2026

▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.
This is the biggest new event of the period and the main force behind the stock's story.
Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.
It is the key financial result of the period and the main negative force on the stock.
New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.
A steady stream of pipeline wins supports long-term growth even as current earnings dip.
Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.
These are new capital-return and demand-side events that affect investor income and product demand.